Merck Expands Popular Line of Guava® Flow Cytometers

• Optical configurations meet needs of any lab, research discipline or individual application
• Product can detect up to 14 parameters from a single sample

Darmstadt, Germany, May 11, 2016 — Merck, a leading science and technology company, is expanding its popular line of Guava® flow cytometers to include a high-power modulated green laser.

The addition of a 532 nanometer laser expands the detection capabilities of the Guava® easyCyte instrument line to enable simultaneous detection of multiple fluorescent proteins. It also offers researchers more spectral choice using fluorescent reagents. More powerful violet, blue and red lasers are now standard in most configurations, meaning the Guava® cytometers are sensitive enough to detect subcellular particles as small as viruses.

Since the discovery and isolation of the genes encoding proteins responsible for biological fluorescence, fluorescent proteins (FPs) have changed life science research. Both mutation of the original green FP and discovery of naturally occurring proteins emitting elsewhere in the spectrum have resulted in FPs of many colors. Merck’s new easyCyte green laser variants meet the need for instrumentation that allows users to analyze heterogeneous biological tissues and systems in a single experiment.

Merck’s Guava® pioneered microfluidics in flow cytometry 15 years ago when the company introduced the first benchtop flow cytometers. This new enhanced optical capability and flexibility has been achieved by Guava® engineers with no increase in instrument size and without sacrificing affordability. Better optical configurations that allow for more meaningful analysis permit a small benchtop footprint. This gives users reduced buffer and sample volumes and dramatically reduces waste when compared with sheath-based flow cytometers.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.